We are gearing up for our annual AI in Drug Discovery summit in a few days. So, for this episode, we focused on some recent AI news coverage. First, GEN senior editor Fay Lin, PhD, visited Seattle recently for some AI-focused meetings. She discusses her experiences in the Emerald City including an exclusive in-person interview with Nobel laureate, David Baker, PhD, on what’s real and what’s hype when it comes to using AI to design proteins de novo.  Then we discuss new research from University of California, San Diego, that used machine learning to identify networks of genes that could be targeted to reprogram cancer stem cells. We also go over some early studies that point to a possible drug candidate for colon cancer.  

Join GEN editors Corinna Singleman, PhD, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. 

Listed below are links to the GEN stories referenced in this episode of Touching Base: 

Brunkow, Ramsdell, Sakaguchi Win Nobel Prize in Physiology or Medicine for Peripheral Immune Tolerance 

Uduak Thomas, GEN, October 6, 2025 

AI in Protein Design: Hype vs. Reality Explained by David Baker 

By Fay Lin, PhD, GEN, October 20, 2025 

Nobel Anniversary: David Baker Keynotes STEM Fundraiser by ARCS Foundation Seattle 

By Fay Lin, PhD, GEN, October 14, 2025 

AI Treatment Reprograms and Triggers Cancer Stem Cells to Self-Destruct 

GEN, October 20, 2025 

The State of AI in Drug Discovery Registration 

Touching Base Podcast 

Hosted by Corinna Singleman, PhD 

Behind the Breakthroughs 

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.